ArticlePloS one2026
Machine learning models based on magnetic resonance imaging for predicting Lymphovascular Invasion in Invasive Breast Cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTreatment strategies for invasive breast cancer require accurate lymphovascular invasion (LVI) predictions. This study aimed to investigate the feasibility and effectiveness of delta radiomics signature based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and radiomics signature based on T2-weighted fat suppressed imaging(T2FS) for assessing LVI in invasive breast cancer. MATERIALS AND
methodsA total of 166 patients with resectable invasive breast cancer who underwent preoperative DCE-MRI and T2FS from July 10, 2020 to December 31, 2023 were enrolled. Radiomics features were extracted from pre-contrast phase (RFpre), second post-contrast phase (RFpost), and Delta radiomics features (RFDelta) calculated as RFpost minus RFpre. Then four radiomics signatures (RST2, RSpre, RSpost, RSDelta) were further developed based on the Random Forest model for RFT2, RFpre, RFpost and RFDelta, respectively. The predictive performance of all signatures was evaluated by receiver operating characteristic (ROC) analysis, with accuracy and area under the curve (AUC) as the main quantitative metrics.
resultsIn the test set, RSDelta (10 features) achieved the highest accuracy of 0.717 and an AUC of 0.764; RSpost (8 features) had an accuracy of 0.565 and an AUC of 0.610; RSpre (7 features) and RST2 (6 features) both showed an accuracy of 0.565 with AUCs of 0.535 and 0.662, respectively. Statistical differences were observed in predictive performance between RSDelta and RSpre, RSpost (both p < 0.05), while no significant difference was found between RSDelta and RST2 (p = 0.239).
conclusionRST2, RSpre, RSpost and RSDelta are all feasible for predicting LVI in invasive breast cancer, and RSDelta outperforms the other three radiomics signatures, which can serve as a potential non-invasive imaging biomarker for LVI prediction in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.